Skip to content

Enhancing Lung Health in Kids with structural Lung Damage and Malformations: a randomized controlled trial on Azithromycin (AZI) for Airway Infection Prevention

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-518730-88-00
Enrollment
150
Registered
2025-11-14
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tracheomalacia, Cystic Lung Malformations, Post-Vascular Ring with central airway compression, Lobar Hyperinflation Syndrome, BronchoPulmonary Dysplasia, Bronchiectasis, Chronic Atelectasis

Brief summary

Difference in the number of respiratory exacerbations between the treatment groups in the intervention period in the intervention period

Detailed description

Difference in duration of exacerbations between the treatment groups in the intervention period, Difference in number of hospital admissions between the treatment groups in the intervention period, Difference in duration of hospital admissions between the treatment groups in the intervention period

Interventions

DRUGZITHROMAX 40 mg/ml pulver till oral suspension

Sponsors

Rigshospitalet
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
0 Years to 17 Years

Design outcomes

Primary

MeasureTime frame
Difference in the number of respiratory exacerbations between the treatment groups in the intervention period in the intervention period

Secondary

MeasureTime frame
Difference in duration of exacerbations between the treatment groups in the intervention period, Difference in number of hospital admissions between the treatment groups in the intervention period, Difference in duration of hospital admissions between the treatment groups in the intervention period

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026